pLV-H2B-iRFP670-p2a-mCerulean-Geminin (1–110)-IRES-Neomycin Citations (2)

Originally described in: Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer.
Kim S, Armand J, Safonov A, Zhang M, Soni RK, Schwartz G, McGuinness JE, Hibshoosh H, Razavi P, Kim M, Chandarlapaty S, Yang HW Cell Rep. 2023 Nov 28;42(11):113198. doi: 10.1016/j.celrep.2023.113198. Epub 2023 Oct 21. PubMed Journal

---

Articles Citing pLV-H2B-iRFP670-p2a-mCerulean-Geminin (1–110)-IRES-Neomycin

Articles
Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models. Kim S, Son E, Park HR, Kim M, Yang HW. J Clin Invest. 2025 Aug 12;135(20):e188839. doi: 10.1172/JCI188839. eCollection 2025 Oct 15. PubMed
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang HW. Elife. 2025 Dec 29;14:RP104545. doi: 10.7554/eLife.104545. PubMed

If you have published an article using this material, please email us at to have your article added to this page.